Thomas McFall

Thomas McFall, PhD, is an Assistant Professor in the Department of Biochemistry at the Medical College of Wisconsin. His research focuses on systems biology approaches to resolve clinical controversies in cancer therapy, particularly in RAS signaling, MAPK pathways, and progesterone receptor dynamics. He holds an MBA and has experience in strategic development for nonprofit and for-profit collaborations.

• Education: PhD in Oncology & Cancer Biology (Wayne State University), Postdoc at Salk Institute, MBA (Davenport University)

Key research interests include synthetic lethality in cancer therapy, mechanisms underlying EGFR inhibitor sensitivity in KRAS-mutant cancers, and the interplay between estrogen and MAPK signaling in ovarian cancer. His work has been published in journals like Science Signaling and Cell Reports.

Recent studies have identified biomarkers for therapeutic response in pancreatic and colorectal cancers, emphasizing precision medicine strategies. McFall’s findings on KRAS G13D mutant sensitivity to EGFR inhibitors have challenged clinical guidelines and advanced mechanistic understanding.

• Scientific Awards: None explicitly listed in the provided text.

Advising and grants: No formal advisees listed, but leadership roles in drug discovery at Ideaya Biosciences and contributions to clinical trial data analysis highlight his collaborative research impact. Current projects integrate systems biology with oncology to improve treatment selection for exceptional responders.

Labs/Teams: His research program combines systems pharmacology, MAPK signaling, and nuclear receptor studies, though specific lab names are not mentioned.